Valuation: Alcon

Market Cap 33.31B 29.26B 26.96B 25.23B 47.28B 3,141B 48.3B 324B 125B 1,550B 125B 122B 5,386B P/E 2026 *
31.7x
P/E 2027 * 24.7x
Enterprise Value 35.91B 31.55B 29.07B 27.2B 50.97B 3,386B 52.06B 349B 135B 1,671B 135B 132B 5,806B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.95x
Free-Float
97.36%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
Manager TitleAgeSince
Chief Executive Officer 60 01/07/2018
Director of Finance/CFO 58 08/04/2019
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 01/07/2018
Director/Board Member 63 01/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33.31B
+1.54%-2.82%-28.02%-0.90% 88.43B
+0.54%+7.75%-0.17%-24.97% 13.85B
-1.44%-0.60% - - 9.37B
-3.52%-15.15%-10.67%+497.74% 1.97B
-4.52%-5.99%-31.53%-64.96% 1.36B
-3.54%-9.80%-47.78%-35.50% 788M
-0.92%-1.68%+6.45%-5.99% 776M
+0.12%+4.67%+55.43%-32.22% 781M
+12.60%+13.26% - - 708M
Average +0.09%-0.94%-8.04%+47.60% 13.11B
Weighted average by Cap. +0.81%-1.43%-23.47%+3.79%

Financials

2026 *2027 *
Net sales 11.13B 9.78B 9.01B 8.43B 15.79B 1,049B 16.13B 108B 41.9B 518B 41.78B 40.87B 1,799B 11.82B 10.38B 9.57B 8.95B 16.78B 1,115B 17.14B 115B 44.51B 550B 44.38B 43.41B 1,911B
Net income 1.09B 953M 878M 822M 1.54B 102B 1.57B 10.55B 4.09B 50.51B 4.07B 3.99B 175B 1.38B 1.21B 1.12B 1.05B 1.96B 130B 2B 13.42B 5.2B 64.22B 5.18B 5.07B 223B
Net Debt 2.6B 2.28B 2.1B 1.97B 3.69B 245B 3.77B 25.27B 9.79B 121B 9.76B 9.54B 420B 1.54B 1.36B 1.25B 1.17B 2.19B 146B 2.24B 15.01B 5.81B 71.86B 5.8B 5.67B 250B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA